PEN.N Hits 20-Day High Amid Positive Market Sentiment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 24 Nov 25
Source: WSJ
Shares of PEN.N surged today, reaching a notable 20-day high as investors reacted positively to recent market developments. The stock's upward momentum signals a potential bullish trend, with strong buying interest observed throughout the trading session. Analysts attribute this breakout to a combination of favorable earnings reports and optimistic forecasts that have bolstered investor confidence in the company's growth prospects. As the stock continues to gain traction, market watchers will be keen to see if this upward trajectory can be sustained in the coming weeks.
Analyst Views on PEN
Wall Street analysts forecast PEN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEN is 344.64 USD with a low forecast of 266.00 USD and a high forecast of 388.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 359.030
Low
266.00
Averages
344.64
High
388.00
Current: 359.030
Low
266.00
Averages
344.64
High
388.00
About PEN
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
